For years, patients with IPF had no approved therapies available ... beta 6 integrin inhibitor STX-100 and FibroGen's connective tissue growth factor (CTGF) blocker FG-3019. Pharma's interest ...

Idiopathic Pulmonary Fibrosis (IPF) is a frightening ... The top-line results revealed that pamrevlumab, which targets connective tissue growth factor, failed to produce an improvement compared ...

Novo Holdings today announced its participation in a €23 million Series A round for Tribune Therapeutics ('Tribune'). The round was led by new investor LifeArc Ventures and joined by Novo Holdings, ...

OliX is developing OLX201—the same molecule as OLX101—for IPF as an inhalable product that also targets the CTGF gene and is delivered locally to the lung. Local delivery reduces ...

Tribune raises EUR 37 million in seed and Series A funding to advance portfolio of therapies targeting central drivers of ...

(RTTNews) - Pliant Therapeutics, Inc. (PLRX) announced the discontinuation of its BEACON-IPF Phase 2b trial evaluating bexotegrast for the treatment of idiopathic pulmonary fibrosis or IPF ...

The company’s lead program, TRX-44, is currently in development for the treatment of fibrotic conditions including idiopathic pulmonary fibrosis ... including CTGF/CCN2 and WISP1/CCN4, on ...

Tribune's lead programme, TRX-44, is currently in development for the treatment of fibrotic conditions including idiopathic pulmonary fibrosis (IPF ... including CTGF/CCN2 and WISP1/CCN4 ...

Programs address the need for disease-modifying therapies targeting root causes of fibrosis Funding will support advancement of CCN-family inhibitor TRX-44 into clinical trials for treatment ...